AstraZeneca Pharma India Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Sanjeev Panchal

Chief executive officer

₹21.1m

Total compensation

CEO salary percentage	24.2%
CEO tenure	1.3yrs
CEO ownership	n/a
Management average tenure	1.1yrs
Board average tenure	1.9yrs

Recent management updates

Recent updates

CEO Compensation Analysis

How has Sanjeev Panchal's remuneration changed compared to AstraZeneca Pharma India's earnings?
Date	Total Compensation	Salary	Company Earnings
Dec 31 2023	n/a	n/a	₹1b
Sep 30 2023	n/a	n/a	₹2b
Jun 30 2023	n/a	n/a	₹1b
Mar 31 2023	₹21m	₹5m	₹993m

Compensation vs Market: Sanjeev's total compensation ($USD253.28K) is below average for companies of similar size in the Indian market ($USD416.21K).

Compensation vs Earnings: Insufficient data to compare Sanjeev's compensation with company performance.

CEO

Sanjeev Panchal (46 yo)

1.3yrs

Tenure

₹21,149,014

Compensation

Dr. Sanjeev Kumar Panchal serves as Country President of AstraZeneca Pharma India Limited since January 01, 2023 and serves as its Managing Director since January 01, 2023. He serves as Director of AstraZe...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Sanjeev Panchal	MD, Country President & Director	1.3yrs	₹21.15m	no data
Bhavana Agrawal	Whole-Time Director & CFO	less than a year	no data	no data
Pratap Bhuvanagiri	Legal Counsel	7.3yrs	₹3.73m	no data
Manasa R.	Company Secretary & Compliance Officer	1.8yrs	no data	no data
Smita Saha	Vice President of Human Resources	no data	₹12.28m	no data
Ayush Agarwal	Interim Business Unit Head of Oncology & Director of Commercial Excellence	less than a year	no data	no data
Praveen Akkinepally	Head of Oncology Business Unit	less than a year	no data	no data
Vimlesh Maheshwari	Finance Controller	no data	no data	no data

1.1yrs

Average Tenure

Experienced Management: 506820's management team is not considered experienced ( 1.1 years average tenure), which suggests a new team.

Board Members

Name	Position	Tenure	Compensation	Ownership
Sanjeev Panchal	MD, Country President & Director	1.3yrs	₹21.15m	no data
Bhavana Agrawal	Whole-Time Director & CFO	less than a year	no data	no data
Revathy Ashok	Independent Non-Executive Director	7.4yrs	₹1.20m	no data
Narayan Seshadri	Independent Chairman of the Board	11.4yrs	₹1.40m	no data
Hooi Chuah	Additional Non-Executive Director	less than a year	no data	no data
Nirula Shilpa Divekar	Independent Non-Executive Director	2.4yrs	₹1.30m	no data
Ankush Nandra	Additional Non-Executive Director	4yrs	no data	no data
Sylvia Lorena Ramon	Non-Executive Director	less than a year	no data	no data

1.9yrs

Average Tenure

51yo

Average Age

Experienced Board: 506820's board of directors are not considered experienced ( 1.9 years average tenure), which suggests a new board.

AstraZeneca Pharma India Management

Management criteria checks 1/4

Key information

Recent management updates

Astrazeneca Pharma India Limited Announces Board Changes

AstraZeneca Pharma India Limited Announces Board Changes

Less than half of directors are independent

Astrazeneca Pharma India Limited Appoints Hooi-Bien Chuah as Additional Director (Non-Executive)

AstraZeneca Pharma India Limited Appoints Praveen Akkinepally as the Business Unit Head Oncology with Effect from November 1, 2023

AstraZeneca Pharma India Limited Announces Executive Changes

Recent updates

Astrazeneca Pharma India Limited Announces Board Changes

Third quarter 2024 earnings released: EPS: ₹6.32 (vs ₹11.72 in 3Q 2023)

New minor risk - Share price stability

AstraZeneca Pharma India Limited Announces Board Changes

AstraZeneca Pharma India Limited to Report Q3, 2024 Results on Feb 08, 2024

Less than half of directors are independent

Astrazeneca Pharma India Limited Appoints Hooi-Bien Chuah as Additional Director (Non-Executive)

AstraZeneca Pharma India Limited to Report Q3, 2024 Results on Nov 09, 2023

AstraZeneca Pharma India Limited Appoints Praveen Akkinepally as the Business Unit Head Oncology with Effect from November 1, 2023

AstraZeneca Pharma India Limited Approves Dividend for the Financial Year 2022-2023

AstraZeneca Pharma India Limited to Report Q1, 2024 Results on Aug 14, 2023

AstraZeneca Pharma India Limited Announces Executive Changes

Full year 2023 earnings released: EPS: ₹39.72 (vs ₹24.64 in FY 2022)

AstraZeneca Pharma India Limited, Annual General Meeting, Aug 14, 2023

Upcoming dividend of ₹16.00 per share at 0.4% yield

Full year 2023 earnings released: EPS: ₹39.72 (vs ₹24.64 in FY 2022)

Astrazeneca Pharma India Limited Announces CFO Changes

AstraZeneca Pharma India Limited to Report Q4, 2023 Results on May 30, 2023

Third quarter 2023 earnings released: EPS: ₹11.72 (vs ₹4.57 in 3Q 2022)

AstraZeneca Pharma India Limited to Report Q3, 2023 Results on Feb 10, 2023

Less than half of directors are independent

AstraZeneca Pharma India Limited Announces Resignation of Gagandeep Singh Bedi as Managing Director, Effective December 31, 2022

Second quarter 2023 earnings released: EPS: ₹13.03 (vs ₹4.78 in 2Q 2022)

Less than half of directors are independent

Second quarter 2023 earnings released: EPS: ₹13.03 (vs ₹4.78 in 2Q 2022)

Astrazeneca Pharma India Limited Receives Import And Market Permission From The Drugs Controller General Of India For Olaparib 100Mg/150Mg

Astrazeneca Pharma India Limited Appoints Shilpa Shridhar Divekar, as an Independent Director

AstraZeneca Pharma India Limited Announces Executive Changes

AstraZeneca Pharma India Limited to Report Q1, 2023 Results on Aug 08, 2022

Full year 2022 earnings released: EPS: ₹24.64 (vs ₹37.32 in FY 2021)

Astrazeneca Pharma India Limited Proposes Final Dividend for the Financial Year 2022

Upcoming dividend of ₹8.00 per share

Full year 2022 earnings released: EPS: ₹24.84 (vs ₹37.32 in FY 2021)

AstraZeneca Pharma India Limited Recommends Final Dividend for the Financial Year 2021-22

Less than half of directors are independent

Third quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Less than half of directors are independent

Regio Biosciences Enters into License Agreement with Astrazeneca for Phase 2A Asset in Peripheral Artery Disease (Pad)

Astrazeneca Pharma India Limited Announces Resignation of Kimsuka Narsimhan as Independent Director, At the Close of Business Hours on February 1, 2022

Full year 2021 earnings released: EPS ₹37.32 (vs ₹28.88 in FY 2020)

Full year 2021 earnings released: EPS ₹37.32 (vs ₹28.88 in FY 2020)

Executive VP, President of Research & Development Oncology Jose Baselga has left the company

Sub: Astrazeneca Pharma India Limited Receives Import and Market Permission in Form CT-20 (Subsequent New Drug Approval) from the Drugs Controller General of India for Osimertinib 40mg/80mg Film Coated Tablets (Tagrissotm)

New 90-day low: ₹3,561

Third quarter 2021 earnings released: EPS ₹8.42 (vs ₹10.68 in 3Q 2020)

BenevolentAI and AstraZeneca Achieve Collaboration Milestone with Novel Ai-Generated Chronic Kidney Disease Target

New 90-day low: ₹4,027

Astrazeneca Pharma India Limited Receives Import And Market Permission In Form CT-20 For Benralizumab 30Mg/Ml Solution For Injection (Fasenra)

Daiichi Sankyo Company, Limited and AstraZeneca Announce the Initiation of TROPION-Lung01

New 90-day high: ₹4,605

Second quarter 2021 earnings released: EPS ₹10.54

Daiichi Sankyo Company, Limited and Astrazeneca’s ENHERTU Has Receives Acceptance for its Supplemental Biologics License Application

AstraZeneca Pharma India Limited Announces Launch of Acalabrutinib 100Mg Capsules (Calquence®)

New 90-day high - ₹3,684

Upcoming Dividend of ₹2.00 Per Share

First quarter earnings released

AstraZeneca Pharma India Limited to Report Q2, 2021 Results on Nov 14, 2020

CEO Compensation Analysis

CEO

Tenure

Compensation

Leadership Team

Average Tenure

Board Members

Average Tenure

Average Age